Acerta Pharma is a leader in the field of covalent binding technology and is applying this technology to create novel, highly selective therapies for cancer. In February 2016, AstraZeneca acquired a majority share of Acerta Pharma via a USD $4 billion investment and is a committed partner to the development of these innovative drug candidates.
Acerta Pharma serves as AstraZeneca’s “Haematologic Oncology Center of Excellence”. As such, it has the responsibility of developing both internally discovered compounds as well as AstraZeneca sourced compounds for hematological malignancies.
The company began operations in 2013 with the vision of combining cutting edge science, unique covalent binding technology, and an experienced and dedicated team in order to deliver novel targeted therapies for patients with cancer.
In February 2016, AstraZeneca made a multibillion-dollar investment in Acerta Pharma for 55% ownership, driven by the lead investigational Bruton tyrosine kinase (BTK) inhibitor, acalabrutinib and the opportunity to build out its haematology/oncology pipeline.
Acalabrutinib is Acerta Pharma’s lead asset and is being studied in over 20 clinical trials for both monotherapy and in combination with other targeted molecules and is under investigation in multiple Phase 3 clinical trials. Acalabrutinib received accelerated approval by the FDA for previously treated Mantle Cell Lymphoma patients.
Discovery and early Development activities include oncology programs for other targeted compounds as monotherapy or in combination with acalabrutinib in a variety of blood-based oncology indications. Over 200 employees are engaged in the development of acalabrutinib and other pipeline compounds for haematologic malignancies.